Over the course of H217, CollPlant announced that it had received orders for its BioInk product from two companies for development of 3D printed organs and orthopaedic devices respectively. In the FY17 results the company announced that the first two orders accounted for NIS0.69m in revenue, bringing revenue for the year to NIS1.67m. One of the clients placed a repeat order, which is expected to be recorded in Q118 results.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.